AMG 420 Treatment of Multiple Myeloma using anti-BCMA BiTE Program is Promising

Amgen releases initial data on AMG 420 Immunotherapy and the initial results in multiple myeloma look very good

AMG 420 Treatment of Multiple Myeloma from Amgen’s anti-BCMA BiTE Program is Promising

By Dr. C.H. Weaver M.D. 9/12/2018

The BiTE® antibody construct represent an innovative immunotherapy approach that helps the body’s immune system target cancer cells. AMG 420 is a BiTE antibody construct drug that acts as a bridge for two proteins, BCMA and CD3 which can induce an immune response in patients with multiple myeloma.1

Blinatumomab was the first of the investigational BiTE® antibody constructs developed and was approved for the treatment of Acute Lymphoblastic Leukemia in 2015.2

This AMG 420 drug candidate stems from the company's anti-BCMA BiTE program. BiTE stands for "bi-specific T-cell engager" technology. This is a type of immunotherapy treatment that induces responses from T-Cells in the patient's own immune system. It does not target the cancer itself, instead AMG 420 consists of two particular proteins, BCMA and CD3, respectively. The BCMA portion binds to an antigen on the surface of a cancer cell, and the CD3 binds to the surface of a T-cell. This bridge forms the way in which Cytotoxic T-Lymphocytes (CTLs) attack cancer cells causing cell lysis. CTLs are white blood cells that enter in and break down the cancer cell through lysis. Lysis means that the cell is broken down, which kills the cancer.

Amgen has reported that 5 complete responses were achieved in individuals with relapsed/refractory multiple myeloma who were treated with AMG 420. Importantly 4 out of 5 patients treated with AMG 420 were MRD-negative, meaning they had no detectable form of disease after treatment and their responses have exceeded 10 months. It is expected that additional information on AMG 420 will be presented at the American Society of Hematology meeting in December.